Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using The Health Improvement Network in the United Kingdom
- 27 April 2018
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (06) , 1101-1112
Abstract
The purpose of this analysis was to assess potential predictors of intra-cranial bleeding (ICB) and gastrointestinal bleeding (GIB) in patients with symptomatic peripheral artery disease (PAD) in UK primary care. Patients with symptomatic PAD diagnosed from 2000 to 2010 were identified from The Health Improvement Network (THIN; N = 28,484). A nested case–control analysis, adjusted for potential confounders, was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for potential predictors of ICB or GIB. For GIB, follow-up was restricted to Hospital Episode Statistics-linked THIN practices. Median follow-up was 6 years. For ICB (153 cases), the OR (95% CI) was 3.85 (1.33–11.13) for previous ICB, 0.90 (0.61–1.34) for treated hypertension, 1.59 (0.65–3.87) for untreated hypertension and 1.38 (0.80–2.36) for current smoking. ORs for ICB were 0.78 (0.50–1.21), 0.40 (0.09–1.82) and 1.27 (0.47–3.47) with use of acetylsalicylic acid (ASA), clopidogrel and warfarin monotherapy, respectively, compared with non-use of such therapy. For GIB (506 cases), the OR was 1.40 (1.05–1.86) for peptic ulcer disease, 3.20 (1.81–5.64) for dual anti-platelet therapy use, 1.96 (1.46–2.64) for non-steroidal anti-inflammatory drug (NSAID) use and 1.01 (0.80–1.28) for proton pump inhibitor use. ORs for GIB were 1.78 (1.39–2.30), 2.03 (1.05–3.93) and 1.25 (0.72–2.16) with ASA, clopidogrel and warfarin monotherapy, respectively, compared with non-use. Previous ICB was a risk factor for ICB. Use of anti-platelet therapy or NSAIDs increased GIB risk. Identifying bleeding predictors could help optimize treatment strategies for patients with PAD.Keywords
This publication has 21 references indexed in Scilit:
- Challenges associated with peripheral arterial disease in womenVascular Health and Risk Management, 2014
- Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AFEuropean Heart Journal, 2013
- Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement NetworkPharmacoepidemiology and Drug Safety, 2012
- Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004Journal of Vascular Surgery, 2012
- ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Validation studies of the health improvement network (THIN) database for pharmacoepidemiology researchPharmacoepidemiology and Drug Safety, 2006
- What Does the Odds Ratio Estimate in a Case-Control Study?International Journal of Epidemiology, 1993
- Health and Deprivation: Inequality and the NorthThe British Journal of Sociology, 1989